Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors
Cristina Mullenix(National Institutes of Health), Arun Rajan(National Cancer Institute), Patrick J. Loehrer(Indiana Cancer Consortium), Yo-Ting Tsai(Comprehensive Blood & Cancer Center), Trina Poretta(Oncology Specialists), Renee N. Donahue(National Institutes of Health), Madison Ballman(National Institutes of Health), Meredith J. McAdams(National Institutes of Health), Jeffrey Schlom(National Cancer Institute), James L. Gulley(National Cancer Institute), Sarthak Gupta(National Institutes of Health), Haobin Chen(Washington University in St. Louis), Shannon Swift(National Institutes of Health)
Cited by 4
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
|Hybridoma|1984|580
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563